Array BioPharma (ARRY) – Analysts’ Recent Ratings Changes

Array BioPharma (NASDAQ: ARRY) has recently received a number of price target changes and ratings updates:

  • 2/7/2018 – Array BioPharma had its price target raised by analysts at Leerink Swann from $19.00 to $20.00. They now have an “outperform” rating on the stock.
  • 2/7/2018 – Array BioPharma had its price target raised by analysts at Stifel Nicolaus from $20.00 to $23.00. They now have a “buy” rating on the stock.
  • 2/6/2018 – Array BioPharma had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $20.00 price target on the stock.
  • 1/22/2018 – Array BioPharma was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating.
  • 1/22/2018 – Array BioPharma had its price target raised by analysts at Stifel Nicolaus from $15.00 to $20.00. They now have a “buy” rating on the stock.
  • 1/21/2018 – Array BioPharma had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $15.00 price target on the stock.
  • 1/4/2018 – Array BioPharma was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company’s proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. “
  • 1/3/2018 – Array BioPharma was given a new $15.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “ARRY and ASLAN (NC) have updated a 2011 agreement for varlitinib, a pan-HER2 inhibitor, providing nearer term cash to ARRY in exchange for commercialization rights (the prior agreement covered development).””
  • 12/22/2017 – Array BioPharma had its price target raised by analysts at Jefferies Group LLC to $13.00. They now have a “buy” rating on the stock.
  • 12/22/2017 – Array BioPharma was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Array BioPharma Inc. (ARRY) opened at $16.87 on Friday. Array BioPharma Inc. has a 52 week low of $6.73 and a 52 week high of $18.24. The company has a debt-to-equity ratio of 0.54, a quick ratio of 5.43 and a current ratio of 5.43. The company has a market capitalization of $3,320.00, a price-to-earnings ratio of -21.91 and a beta of 2.03.

Array BioPharma (NASDAQ:ARRY) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. Array BioPharma had a negative return on equity of 154.43% and a negative net margin of 98.51%. The firm had revenue of $42.21 million for the quarter, compared to analyst estimates of $26.81 million. During the same quarter last year, the company earned ($0.14) EPS. The company’s revenue was down 5.2% on a year-over-year basis. equities analysts forecast that Array BioPharma Inc. will post -0.99 earnings per share for the current year.

In other news, CFO Jason Haddock sold 7,500 shares of Array BioPharma stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $13.73, for a total value of $102,975.00. Following the transaction, the chief financial officer now owns 36,368 shares in the company, valued at approximately $499,332.64. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Andrew R. Robbins sold 282,874 shares of Array BioPharma stock in a transaction on Monday, December 18th. The shares were sold at an average price of $10.72, for a total value of $3,032,409.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,131,545 shares of company stock worth $12,315,221. Corporate insiders own 3.18% of the company’s stock.

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Receive News & Ratings for Array BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit